CALL/VERTEX PHARMACEUTICALS/600/0.1/21.06.24 | Real-time BOERSE MUENCHEN 12:27:09 2024-05-30 EDT | ||
| 0.008 EUR | +60.00% |
|
| Current month | -50.00% | ||
| 1 month | -54.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.008 | +60.00% |
| 24-05-29 | 0.005 | -16.67% |
| 24-05-28 | 0.006 | 0.00% |
| 24-05-27 | 0.006 | 0.00% |
| 24-05-24 | 0.006 | +200.00% |
Real-time BOERSE MUENCHEN
Last update May 30, 2024 at 12:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP93BS |
| ISIN | DE000GP93BS5 |
| Date issued | 2023-07-17 |
| Strike | 600 $ |
| Maturity | 2024-06-21 (22 Days) |
| Parity | 10 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.339 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.15 € |
| Spread % | 93.75% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
441.1
USD
Average target price
462.8
USD
Spread / Average Target
+4.92%
- Stock Market
- Warrants
- Warrant
